- Home
- NRXP vs MTNB Comparison
NRXP vs MTNB Comparison
Compare NRXP & MTNB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NRXP | MTNB |
|---|---|---|
| Founded | 2015 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 151.1M | 5.2M |
| IPO Year | 2017 | 2014 |
Fundamental Metrics
Financial Performance| Metric | NRXP | MTNB |
|---|---|---|
| Price | $3.40 | $0.20 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 4 | 0 |
| Target Price | ★ $38.25 | N/A |
| AVG Volume (30 Days) | 702.7K | ★ 938.3K |
| Earning Date | 05-14-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 69.70 | 59.84 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,225,000.00 | $119,750.00 |
| Revenue This Year | $2,547.84 | N/A |
| Revenue Next Year | $1,591.73 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.65 | $0.17 |
| 52 Week High | $5.06 | $2.14 |
Technical Indicators
Market Signals| Indicator | NRXP | MTNB |
|---|---|---|
| Relative Strength Index (RSI) | 46.05 | 36.78 |
| Support Level | $3.09 | $0.18 |
| Resistance Level | $3.50 | $0.27 |
| Average True Range (ATR) | 0.15 | 0.01 |
| MACD | 0.00 | 0.01 |
| Stochastic Oscillator | 20.27 | 51.93 |
Price Performance
Historical ComparisonAbout NRXP NRX Pharmaceuticals Inc.
NRX Pharmaceuticals Inc is a clinical-stage, small-molecule pharmaceutical company that develops and plans to distribute novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. The company is developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior.
About MTNB Matinas Biopharma Holdings Inc.
Matinas BioPharma Holdings Inc is a clinical-stage biopharmaceutical company with a focus on identifying and developing novel pharmaceutical products. The firm's pipeline includes MAT2203, MAT2501, and others. Its LNC platform enables safe, intracellular, oral- delivery of small molecules and small oligonucleotides.